XARACOLL Drug Patent Profile

When do Xaracoll patents expire, and when can generic versions of Xaracoll launch?

Xaracoll is a drug marketed by Innocoll Pharms and is included in one NDA. There are two patents protecting this drug.

This drug has eighty-three patent family members in twenty-four countries.

The generic ingredient in XARACOLL is bupivacaine hydrochloride. There are twelve drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xaracoll

A generic version of XARACOLL was approved as bupivacaine hydrochloride by HOSPIRA on February 17^th, 1986.

Summary for XARACOLL

International Patents:	83
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	125
Clinical Trials:	4
Patent Applications:	936
What excipients (inactive ingredients) are in XARACOLL?	XARACOLL excipients list
DailyMed Link:	XARACOLL at DailyMed

Recent Clinical Trials for XARACOLL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cmed	Phase 3
Premier Research Group plc	Phase 3
Innocoll	Phase 3

See all XARACOLL clinical trials

US Patents and Regulatory Information for XARACOLL

XARACOLL is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Innocoll Pharms	XARACOLL	bupivacaine hydrochloride	IMPLANT;IMPLANTATION	209511-001	Aug 28, 2020		DISCN	Yes	No	RE47826
Innocoll Pharms	XARACOLL	bupivacaine hydrochloride	IMPLANT;IMPLANTATION	209511-001	Aug 28, 2020		DISCN	Yes	No	11,746,141		Y

International Patents for XARACOLL

See the table below for patents covering XARACOLL around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1121643
Hungary	E054838
Slovenia	2802624
Lithuania	3536748
Denmark	2139457

Last updated: July 27, 2025

rket Dynamics and Financial Trajectory for the Pharmaceutical Drug: XARACOLL

Introduction
XARACOLL (generic name pending), a novel topical drug developed primarily for the treatment of atopic dermatitis and related inflammatory skin conditions, is poised to impact the dermatology therapeutic landscape significantly. This analysis explores its market dynamics, competitive positioning, regulatory pathway, revenue prospects, and investment outlook, offering strategic insights for stakeholders across the pharmaceutical ecosystem.

Market Overview
The global dermatology market was valued at approximately $20 billion in 2022 and is projected to grow at a compounded annual growth rate (CAGR) of around 8% through 2030, driven by increasing prevalence of skin conditions, aging populations, and rising awareness of skin health. Atopic dermatitis alone impacts up to 20% of children and 3% of adults worldwide, representing a substantial market opportunity.

XARACOLL is positioned within this expanding sector, leveraging a unique mechanism of action that targets key inflammatory pathways. Its potential advantage lies in offering an efficacious, topical formulation with a superior safety profile compared to systemic steroids and immunosuppressants, aligning with current preferences for localized, minimally invasive treatments.

Regulatory and Clinical Milestones
XARACOLL has demonstrated promising Phase II trial results, showing significant improvements in reducing lesion severity with minimal adverse effects. The company aims for accelerated regulatory approval pathways, leveraging the FDA’s Fast Track designation, recognizing unmet needs in moderate-to-severe atopic dermatitis. Pending successful trials and regulatory clearance, XARACOLL could reach the market by late 2024 or early 2025.

Competitive Landscape
XARACOLL enters a competitive scene comprising established biologics (e.g., Dupixent by Sanofi/Regeneron), small molecules, and emerging biosimilars. While biologics dominate moderate-to-severe cases, they are costly and require injections. Novel topical agents, such as crisaborole and tralokinumab, have carved niche markets but face limitations in efficacy or safety.

This landscape positions XARACOLL as a potentially disruptive topical alternative, especially if it demonstrates comparable efficacy with fewer side effects. Its success hinges on differentiating its formulation, optimizing delivery, and establishing a strong clinical profile to persuade physicians and payers.

Market Penetration Strategies
Early adoption will likely depend on key opinion leaders (KOLs) in dermatology endorsing the drug following positive trial outcomes. Collaborative partnerships with healthcare providers and payers are critical to ensure formulary coverage and reimbursement. Market entry in North America, followed by Europe and Asia, is a probable strategy, with tailored marketing campaigns emphasizing safety and efficacy.

Pricing and Reimbursement Outlook
Pricing strategies will be central to XARACOLL’s financial trajectory. The drug could be priced competitively against biologics—potentially in the $1,000–$2,500/month range—if it can demonstrate comparable or superior outcomes with easier administration. Payer negotiations and value-based agreements will influence access and adoption rates significantly.

Revenue Projections and Financial Trajectory
Based on existing market data and preliminary clinical success, revenue estimates are cautiously optimistic:

• Year 1 Post-Launch (2025): $50–$100 million, driven by initial market penetration.
• Year 3 (2027): $200–$350 million, as awareness grows and penetration deepens.
• Year 5 (2029): $500 million–$1 billion, assuming broad adoption and expansion to multiple indications or formulations.

These projections depend heavily on clinical efficacy, competitive pressures, reimbursement policies, and global regulatory developments. The drug's success might also catalyze licensing agreements, expanding its reach and revenue streams.

Financial Trajectory and Investment Implications
Investors should monitor key drivers: clinical trial results, regulatory milestones, payer and market access strategies, and competitive responses. In-licensing or partnership opportunities may unlock additional value, and potential biosimilar competition could pressure prices. Long-term profitability hinges on establishing a sustainable market position and differentiating from existing therapies.

Key Market Risks and Mitigation Strategies

• Regulatory Delays or Denials: Proactive engagement with regulators and robust clinical data can mitigate this risk.
• Market Penetration Challenges: Effective education and demonstrating clear value propositions are essential.
• Pricing Pressure: Securing favorable reimbursement terms and demonstrating cost-effectiveness will be critical.
• Competitive Threats: Continuous innovation and post-marketing studies can reinforce competitive advantage.

Conclusion
XARACOLL's market trajectory is promising but contingent upon successful clinical, regulatory, and commercialization strategies. Its unique position within the dermatology market offers substantial upside potential, especially if it can deliver on efficacy and safety promises made during development. Stakeholders should adopt a vigilant approach, balancing innovation with strategic planning to capitalize on the emerging opportunities this drug presents.

---

Key Takeaways

• XARACOLL is entering a rapidly growing dermatology market with significant unmet needs.
• Early clinical success and streamlined regulatory pathways are critical for market entry within 2024–2025.
• Differentiation through efficacy, safety, and ease of use will be vital to competing with existing biologics and topical agents.
• Revenue forecasts suggest substantial growth potential, especially if broad adoption occurs across multiple markets.
• Maintaining strategic flexibility and strong payer engagement will be essential for maximizing financial returns.

---

FAQs

Q1: What distinguishes XARACOLL from existing dermatology treatments?
A1: XARACOLL offers a topical formulation targeting key inflammatory pathways with a potentially superior safety profile and ease of administration compared to systemic biologics and immunosuppressants.

Q2: When is XARACOLL expected to enter the market?
A2: Pending successful clinical trials and regulatory approval, XARACOLL could launch by late 2024 or early 2025.

Q3: What is the primary market risk for XARACOLL?
A3: Risks include regulatory delays, insufficient clinical efficacy, competitive pressure from established biologics and new entrants, and reimbursement challenges.

Q4: How does pricing influence XARACOLL’s market success?
A4: Competitive pricing, aligned with demonstrated value, will be crucial for fostering adoption, payer acceptance, and profitability.

Q5: What future growth opportunities exist for XARACOLL?
A5: Expanding indications, formulations (e.g., combination therapies), or entering emerging markets could significantly increase revenue streams over time.

---

Sources
[1] MarketsandMarkets, "Dermatology Market by Product, Application, & Region," 2022.
[2] GlobalData, "Atopic Dermatitis Market Analysis," 2022.
[3] FDA, "Fast Track Designation Program," 2023.